protein
| PHR1 (through a PDZ domain interaction) |
|
binding partner for the cadherin-associated protein, beta-catenin |
|
interacting with GRM5 through its second PDZ domain (can selectively modulate GRM5 signaling, which may contribute to cell-specific regulation of GRM5 activity) |
|
interacting with MCC |
|
bind to P2RY1, and GRM5 through its PDZ domain |
|
competes with SLC9A3R2 to negatively regulate LPA2 receptor signaling in colon cancer cells |
|
acts synergistically with WNK4 by stabilizing TRPV5 at the plasma membrane to maintain the positive regulation of WNK4 on TRPV5 |
|
cAMP-dependent inhibition of SLC9A3 activity requires either SLC9A3R1 or SLC9A3R2 |
|
SLC9A3R1 and SLC9A3R2 are SCARB1 protein binding partners that play a negative role in the regulation of SCARB1 expression, selective CE (cholesteryl ester) transport, and steroidogenesis |
|
SLC9A3R1 interacts with SLC1A3 during ER export, while SLC9A3R2 interacts with SLC1A3 in the secretory pathway from the ERGIC to the plasma membrane, thereby modulating the cell surface expression of SLC1A3 |
|
PDZ-mediated interaction of SLC9A3R2 and LPAR2, a cellular event implicated in CFTR channel regulation |
|
ESR1-associated coactivator that interacts predominantly with the AF1 domain of the nuclear receptor |
|
SLC9A3R1, SLC9A3R2 down-regulated SCARB1 at least in part via the ubiquitin/proteasome pathway |